Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 567

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 567
---
 even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. 

Under the supervision and with the participation of our management, including our CEO and CFO, and under the oversight of our Board of Directors, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2024 based on criteria related to internal control over financial reporting described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013 Framework).

Based on management's assessment using the criteria set forth above, management concluded that the Company's internal control over financial reporting was effective as of December 31, 2024. 

Our independent registered public accounting firm KPMG LLP, who audited our consolidated financial statements included in this Annual Report on Form 10-K, issued an opinion on the effectiveness of the Company’s internal control over financial reporting. KPMG LLP’s report is included in this Annual Report on Form 10-K.

Changes in Internal Control over Financial Reporting

Our management, including our CEO and CFO, evaluated changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2024. There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 that occurred during the quarter ended December 31, 2024, that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B.     OTHER INFORMATION.

Insider Trading Arrangements and Policies

The table below lists the  insider trading arrangements adopted or terminated during the fourth quarter of 2024.

Name and Title of Director or OfficerRule 10b5-1 Trading Arrangement(1)Trading Arrangement Adopted or TerminatedDate of Adoption or TerminationDuration of Trading ArrangementAggregate Number of Securities to be Purchased Pursuant to Trading ArrangementAggregate Number of Securities to be Sold Pursuant to Trading ArrangementJack Khattar, President, Chief Executive Officer and DirectorYesAdoptedNovember 14, 2024First Transaction Date throughFebruary 24, 2027580,000580,000(2)____________________________________(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).(2) This trading arrangement covers the exercise and sale of stock options,